We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AMO Pharma

News List

AMO Pharma launches late-stage study of CMD candidate pharmatimes
December 24, 2020
London-headquartered AMO Pharma has announced the launch of a ‘pivotal’ phase III study of its congenital myotonic dystrophy (CDM1) candidate AMO-02 (tideglusib).
AMO Pharma Sees Positive Results in Phase II Trials biospace
March 19, 2018
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood biospace
March 16, 2018
AMO Pharmaceuticals, Inc. announced today that it has provided final data for Phase 2 proof-of-concept studies for AMO-02
AMO Pharma Enters into Collaboration Agreement with Ranedis Pharmaceuticals for Development of RND-0 americanpharmaceuticalreview
March 15, 2017
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, today announced it has entered a collaboration agreement with Ranedis Pharmaceuticals, a privately held U.S.